Navigation Links
Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Date:5/18/2011

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival (the primary endpoint of the study) and time-to-progression. The study evaluated Nexavar in combination with a chemotherapeutic agent, either gemcitabine or capecitabine. The data will be presented on June 6, 2011, at 11:45 a.m. during the oral abstract session at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Clifford Hudis, M.D., Chief of the Breast Cancer Medicine Service and attending physician at the Memorial Sloan-Kettering Cancer Center, as well as Professor of Medicine at Weill Cornell Medical College, reported that patients receiving Nexavar in addition to standard chemotherapy agents obtained a progression-free survival benefit with median of 3.4 months to progression versus 2.7 (HR=0.65, one-sided p-value=0.01). Time-to-progression was similarly improved from a median of 3.6 months from 2.7 (HR=0.64; one-sided p-value=0.009) in this pre-treated population.

"These results demonstrate the importance of continuing to evaluate antiangiogenic compounds in breast cancer, and their study should remain a high priority for the research community," said Dr. Hudis.

"These data are similar to those observed in our previous Phase 2 trial evaluating Nexavar in combination with capecitabine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations for Onyx Pharmaceuticals.  "Onyx and Baye
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
4. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
5. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
6. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
9. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
10. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
11. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... A hernia is condition in which a tissue, ... of a weak muscle area. Obesity, poor nutrition, smoking, and ... causes of hernias. There are several types of hernia such ... is when part of the abdominal tissue/organ protrudes into the ... of the umbilicus. A hiatal hernia is when a portion ...
(Date:11/26/2014)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Research and Consultancy focusing on the active pharmaceutical ingredient ... Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In ... Market – Forecast to 2020 , ...
(Date:11/26/2014)... YORK , Nov. 25, 2014  Medtronic,s ... Covidien has been widely discussed in the ... it,s also creating a stronger leading player in ... to Kalorama Information.  The healthcare market research firm ... systems will feature a diverse set of solutions ...
Breaking Medicine Technology:Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
... from a 52-week phase 3,study (LEADTM 3) of ... once-daily,human GLP-1 analog, were published online today in ... alone, produces statistically,significant and sustained improvements in blood ... as compared with glimepiride, a widely used,oral anti-diabetic ...
... Calif., Sept. 25 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... symptomatic intracranial hemorrhage in an earlier European,trial of ... ischemic,stroke may be minimized with avoidance of prolonged ... pressure entry criteria., The data, presented today ...
Cached Medicine Technology:Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 2Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 3Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials 2Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials 3Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials 4
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated litigation ... LLP reports. , Documents recently updated in ... records included in the state proceeding, all of ... bipolar disorder and other psychiatric conditions. Many of ...
(Date:11/27/2014)... WEDNESDAY, Nov. 26, 2014 (HealthDay News) -- Most babies ... a cold, the U.S. Food and Drug Administration says. ... be given to children younger than 2 because they ... agency warned. American adults average about three colds ... children get a cold, parents might want to give ...
(Date:11/27/2014)... (HealthDay News) -- Thanksgiving meals can pose a challenge ... an expert says. Many traditional Thanksgiving dishes -- ... -- are gluten-free, but "when it comes to pies, ... considered," Dr. Anca Safta, director of the Gluten and ... Center in North Carolina, said in a center news ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... Satisfaction Can Lead to Relationship, Quality-of-Life ... ... Leading sexual wellness experts,who attended a satellite symposium of the American ... agreed that,better intimacy can lead to better relationships and ultimately, better,overall ...
... threat, study finds, , , WEDNESDAY, Nov. 12 (HealthDay News) -- Whether ... you have a higher risk of dying than someone of normal ... to collect their weight around the middle -- apple-shaped -- face ... tends to settle in their hips and thighs -- pear-shaped. ...
... Medical Simulation Corporation (MSC),announces a new partnership with the ... and education services for USF Health hospital partners and ... education. The MSC SimSuite Education Center is located at ... , "MSC is excited to partner with USF Health ...
... cost-containment. , ... Alexandria, VA (Vocus) November 12, 2008 ... Chain Drug Stores (NACDS) Steven C. Anderson, IOM, CAE issued a ... Finance Committee Chairman Max Baucus (D-MT) today:, , , , ,“It ...
... that Hydrates and Soothes Young Throats Now Available,Across ... As cough and cold season,rapidly approaches, Integrated ... and nutrition products has launched its newest product,in ... product is a perfect choice for parents who ...
... industry award for 2008, WASHINGTON, Nov. ... of furniture for healthcare environments, today announced ... Nightingale Award at the,annual Healthcare Design 08 ... workspace solution, SYNC(TM)., (Photo: http://www.newscom.com/cgi-bin/prnh/20081112/AQW138 ...
Cached Medicine News:Health News:Experts at American Society for Reproductive Medicine (ASRM) Satellite Symposium Reach Consensus: Better Intimacy = Better Overall Well-Being 2Health News:Experts at American Society for Reproductive Medicine (ASRM) Satellite Symposium Reach Consensus: Better Intimacy = Better Overall Well-Being 3Health News:Excess Weight Ups Risk of Death, No Matter Where It Collects 2Health News:Medical Simulation Corp. announces partnership with University of South Florida 2Health News:As Chairman Baucus Outlines Vision for Healthcare Reform, NACDS Emphasizes Pharmacy's Essential Role in Any Successful Overhaul 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 3Health News:Nurture(R) by Steelcase Wins Second Consecutive Nightingale Award for SYNC(TM) Caregiver Workspace Solution 2Health News:Nurture(R) by Steelcase Wins Second Consecutive Nightingale Award for SYNC(TM) Caregiver Workspace Solution 3
Shoulder rasp...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
85 left angled suture passer....
45 right angled suture passer....
Medicine Products: